Insights into the Antibacterial Mechanism of PEGylated Nano-Bacitracin A Against Streptococcus pneumonia: Both Penicillin-Sensitive and Penicillin-Resistant Strains [Corrigendum]

Hong W, Liu L, Zhang Z, Zhao Y, Zhang D, Liu M. Int J Nanomedicine. 2018;13:6297–6309.

The authors have advised due to an error that occurred inadvertently at the time of figure assembly, Figure 1A on page 6302 is incorrect. The correct Figure 1 is as follows.

Figure 1.

The confocal microscope images of S. pneumonia ATCC 49619 (A) and S. pneumonia 16167 (B) stained by LIVE/DEAD after incubation with PEGylated Nano-BA_12K, BA solution, and Penicillin G for 0.5, 1, 2, 4, 8, and 12 hours at 37°C.

Abbreviation: BA, bacitracin A.

The authors also advised that there are errors in Figure 7C, D and E on page 6306. The correct Figure 7 is as follows.

Figure 7.

Cytoplasmic membrane potential variation of S. pneumonia ATCC 49619 (A) and S. pneumonia 16167 (B) treated with PEGylated Nano-BA_12K at 1× MICs, as assessed by the release of the membrane potential-sensitive dye disC₃-5. The fluorescence intensity was monitored at a λ_ex =622 nm and λ_em =670 nm as a function of time. Effect of PEGylated Nano-BA_12K on the cytoplasmic membrane permeability of S. pneumonia ATCC 49619 (C) and S. pneumonia 16167 (D). PEGylated Nano-BA_12K-induced calcein release as a function of time. PEGylated Nano-BA_12K was added to PTG/CL SUVs encapsulated with calcein (E). The graphs were derived from average values of three independent trials.

Abbreviations: BA, bacitracin A; CL, caidiolipin; PG, phosphatidylglycerol; MIC, minimal inhibitory concentration; SUV, small unilamellar vesicle.

The authors apologize for these errors and advise they do not affect the results and conclusions of the paper.